This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Combination will create a Canadian Health Champion spanning generic, biosimilar and branded pharmaceuticals
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Establishment of 220 smart classrooms across Uttar Pradesh, Uttarakhand, and Himachal Pradesh
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis
Project achieves 30% reduction in hospital acquired infections and 24% reduction in the incidence of multi-drug resistant organisms
The restructuring aims to create synergies across the business and strengthen capital structure
Studies will Investigate Antidepressant Properties of Ketamir to Position for Initial IND Application in 2024
Subscribe To Our Newsletter & Stay Updated
